Dexrazoxane Dosing for Cardioprotection

Standard Dosing Regimen

• The American Society of Clinical Oncology recommends using a 10:1 dexrazoxane-to-doxorubicin ratio as the established standard based on randomized controlled trials demonstrating cardioprotective efficacy 1, 2, 3
• Administer dexrazoxane via slow IV push or rapid drip IV infusion, with a total elapsed time not exceeding 30 minutes from start of dexrazoxane to start of anthracycline 1
• A 10:1 ratio with epirubicin is reasonable, though the optimal dose ratio remains undetermined 1, 2, 4
• Clinical trials used ratios ranging from 6.25:1 to 10:1 for epirubicin 1, 2
• High-dose dexrazoxane (900-1200 mg/m²) increases epirubicin clearance and decreases AUC, suggesting potential pharmacologic interaction 1, 2

Clinical Context and Monitoring

• Continue cardiac monitoring despite dexrazoxane use, with frequent monitoring after cumulative doxorubicin doses of 400 mg/m² 1, 2, 5
• Repeat monitoring at 500 mg/m² and subsequently after every 50 mg/m² of doxorubicin 1, 2, 5
• Strongly consider terminating therapy if LVEF declines below institutional normal limits or clinical CHF develops 1, 2

Special Populations

• There is insufficient evidence for use of dexrazoxane in patients with pre-existing cardiac risk factors or underlying cardiac disease 1, 2, 4

Alternative Indication: Anthracycline Extravasation

• For anthracycline extravasation, a completely different dosing regimen applies: 1000 mg/m² on days 1-2, then 500 mg/m² on day 3, starting within 6 hours of extravasation 6, 7, 8